Sub-study of Belantamab Mafodotin (GSK2857916) in Combination with Nirogacestat in Participants with RRMM

Trial Identifier: 208887 Sub Study 3
Sponsor: GlaxoSmithKline
Start Date: June 2020
Primary Completion Date: April 2025
Study Completion Date: March 2027
Condition: Myeloma

Trial Locations

Country Location
Australia, VIC Fitzroy, VIC, Australia, 3065
Canada, BC Vancouver, BC, Canada, V5Z1M9
Canada, NS Halifax, NS, Canada, B3H 1V7
France Lille, France, 59037
France VILLEJUIF CEDEX, France, 94805
Germany Frankfurt, Germany, 60590
Germany Kiel, Germany, 24105
Germany Leipzig, Germany, 04103
Greece Athens, Greece, 11528
Netherlands UTRECHT, Netherlands, 3584 CX
Norway Oslo, Norway, 0450
Poland Katowice, Poland, 40-519
Poland Lodz, Poland, 93-513
Poland Lublin, Poland, 20-081
Republic of Korea Incheon, Republic of Korea, 21565
Republic of Korea Seoul, Republic of Korea, 06351
Republic of Korea Seoul, Republic of Korea, 06591
Republic of Korea Ulsan, Republic of Korea, 44033
Russian Federation Moscow, Russian Federation, 125284
Spain Badalona, Spain, 08916
Spain Madrid, Spain, 31008
Spain Madrid, Spain, 28041
Spain Pozuelo de AlarcOn Madr, Spain, 28223
Sweden FALUN, Sweden, SE-791 82
Sweden STOCKHOLM, Sweden, SE-141 86
United States, GA Atlanta, GA, United States, 30322
United States, MA Boston, MA, United States, 02215
United States, MI Grand Rapids, MI, United States, 49546
United States, WI Madison, WI, United States, 53792